Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“throughout the disease course individuals with EOT2D have consistently higher glucose levels than those with later-onset T2DM, leading to a more than three-fold increase in cumulative glycemic exposure by the age of 75 years [50].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Large-scale physical activity data reveal worldwide activity inequality
Althoff, T., Sosič, R., Hicks, J. L., King, A. C., Delp, S. L., & Leskovec, J. (2017) · Nature · doi:10.1038/nature23018 · Cited by 1,000
Type 2 diabetes in adolescents and young adults
Lascar, N., Brown, J., Pattison, H., Barnett, A. H., Bailey, C. J., & Bellary, S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30186-9 · Cited by 824
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Potential overtreatment of diabetes mellitus in older adults with tight glycemic control
Lipska, K. J., Ross, J. S., Miao, Y., Shah, N. D., Lee, S. J., & Steinman, M. A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7345 · Cited by 408
Research works printed but not linked: 39
- RR Holman, 2008, 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes, New England Journal of Medicine, 359, 1577, 10.1056/NEJMoa0806470 · DOI · Paper page
- R Roussel, 2018, Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions, Diabetes Obes Metab, 20, 238, 10.1111/dom.13033 · DOI · Paper page
- JB Brown, 2004, The Burden of Treatment Failure in Type 2 Diabetes, Diabetes Care, 27, 1535, 10.2337/diacare.27.7.1535 · DOI · Paper page
- GA Nichols, 2014, The Association Between Different A1C-Based Measures of Glycemia and Risk of Cardiovascular Disease Hospitalization, Diabetes Care, 37, 167, 10.2337/dc13-1300 · DOI
- RPT van Wijngaarden, 2017, Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study, Diabetes Ther, 8, 1097, 10.1007/s13300-017-0301-4 · DOI
- JCN Chan, 2014, Premature Mortality and Comorbidities in Young-onset Diabetes: A 7-Year Prospective Analysis, The American Journal of Medicine, 127, 616, 10.1016/j.amjmed.2014.03.018 · DOI · Paper page
- C Ke, 2019, Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes: A Population-Based Cohort Study, Annals of Internal Medicine, 170, 145, 10.7326/M18-1900 · DOI · Paper page
- ME Pavkov, 2006, Effect of Youth-Onset Type 2 Diabetes Mellitus on Incidence of End-Stage Renal Disease and Mortality in Young and Middle-Aged Pima Indians, JAMA, 296, 421, 10.1001/jama.296.4.421 · DOI · Paper page
- AO Steinarsson, 2018, Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register, Diabetologia, 61, 599, 10.1007/s00125-017-4532-8 · DOI · Paper page
- DH van Raalte, 2011, Glucolipotoxicity and beta cells in type 2 diabetes mellitus: Target for durable therapy?, Diabetes Research and Clinical Practice, 93, S37, 10.1016/S0168-8227(11)70012-2 · DOI
- LA Donnelly, 2018, Rates of glycaemic deterioration in a real-world population with type 2 diabetes, Diabetologia, 61, 607, 10.1007/s00125-017-4519-5 · DOI · Paper page
- TM Wallace, 2002, Coefficient of failure: a methodology for examining longitudinal β-cell function in Type 2 diabetes, Diabetic Medicine, 19, 465, 10.1046/j.1464-5491.2002.00718.x · DOI
- C Ke, 2020, Cardiovascular Outcomes Trials in Type 2 Diabetes: Time to Include Young Adults, Diabetes, Obesity and Metabolism, 22, 3, 10.1111/dom.13874 · DOI · Paper page
- TODAY Study Group, 2012, A clinical trial to maintain glycemic control in youth with type 2 diabetes, N Engl J Med, 366, 2247, 10.1056/NEJMoa1109333 · DOI · Paper page
- RISE Consortium, 2019, Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults, Diabetes, 68, 1670
- J Quan, 2017, Diabetes incidence and prevalence in Hong Kong, China during 2006–2014, Diabet Med, 34, 902, 10.1111/dme.13284 · DOI
- IT Lau, 2017, A Clinical Practice Guideline to Guide a System Approach to Diabetes Care in Hong Kong, Diabetes Metab J, 41, 81, 10.4093/dmj.2017.41.2.81 · DOI
- GM Leung, 2005, The ecology of health care in Hong Kong, Social Science & Medicine, 61, 577, 10.1016/j.socscimed.2004.12.029 · DOI
- JCN Chan, 2011, The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry, Curr Cardiovasc Risk Rep, 5, 230, 10.1007/s12170-011-0172-6 · DOI
- C Ke, 2020, Development and validation of algorithms to classify type 1 and 2 diabetes according to age at diagnosis using electronic health records, BMC Med Res Methodol, 20, 1
- J Levy, 1998, Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study, Diabetic Medicine, 15, 290, 10.1002/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M · DOI
- D Sherifali, 2010, The Effect of Oral Antidiabetic Agents on A1C Levels: A systematic review and meta-analysis, Diabetes Care, 33, 1859, 10.2337/dc09-1727 · DOI · Paper page
- ES Mearns, 2015, Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis, PLoS ONE, 10, e0125879, 10.1371/journal.pone.0125879 · DOI · Paper page
- KGMM Alberti, 2009, Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 · DOI · Paper page
- RC Turner, 1976, Beta-cell function improved by supplementing basal insulin secretion in mild diabetes, Br Med J, 1, 1252, 10.1136/bmj.1.6020.1252 · DOI · Paper page
- RCW Ma, 2013, Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States, Ann NY Acad Sci, 1281, 64, 10.1111/nyas.12098 · DOI · Paper page
- H Wu, 2020, Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study, Cardiovascular Diabetology, 19, 60, 10.1186/s12933-020-01039-y · DOI
- Z Gao, 2020, Annual decline in β-cell function in patients with type 2 diabetes in China, Diabetes Metab Res Rev, e3364
- Y Lu, 2018, The Association of Built Environment and Physical Activity in Older Adults: Using a Citywide Public Housing Scheme to Reduce Residential Self-Selection Bias, Int J Environ Res Public Health, 15, 1973, 10.3390/ijerph15091973 · DOI
- SV Edelman, 2017, Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control, Diabetes Care, 40, 1425, 10.2337/dc16-1974 · DOI · Paper page
- YG Kim, 2013, Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis, Diabetologia, 56, 696, 10.1007/s00125-012-2827-3 · DOI · Paper page
- TME Davis, 2018, Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), Diabetes, Obesity and Metabolism, 20, 1427, 10.1111/dom.13242 · DOI
- JH Ohn, 2016, 10-year trajectory of β-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study, The Lancet Diabetes & Endocrinology, 4, 27, 10.1016/S2213-8587(15)00336-8 · DOI · Paper page
- MCY Ng, 2001, Familial Early-Onset Type 2 Diabetes in Chinese Patients: Obesity and genetics have more significant roles than autoimmunity, Diabetes Care, 24, 663, 10.2337/diacare.24.4.663 · DOI · Paper page
- AT Hattersley, 2017, Precision diabetes: learning from monogenic diabetes, Diabetologia, 60, 769, 10.1007/s00125-017-4226-2 · DOI · Paper page
- J-L Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial, The Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 · DOI · Paper page
- KS Lam, 1998, Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study, Diabetes Care, 21, 1154, 10.2337/diacare.21.7.1154 · DOI · Paper page
- JC Chan, 1998, An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group, Diabetes Care, 21, 1058, 10.2337/diacare.21.7.1058 · DOI · Paper page
- LL Lim, 2018, Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis, Diabetes Care, 41, 1312, 10.2337/dc17-2010 · DOI · Paper page
Cited by
Wu, H., Yang, A., Lau, E. S. H., Zhang, X., Fan, B., Ma, R. C. W., Kong, A. P. S., Chow, E., So, W.-Y., Chan, J. C. N., et al. (2024) · PLOS Medicine · doi:10.1371/journal.pmed.1004327 · Cited by 24
Self-citationManagement of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
Designing a regional clinical service for people with early‐onset type 2 diabetes in England
Goldney, J., Alabraba, V., Sarkar, P., Morgan, H., Hamza, M., Skarlatos, M., Slater, T., Sargeant, J. A., O'Callaghan, R., Hadjiconstantinou, M., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.15479 · Cited by 7
Metadata
- Authors
- Ke, C., Stukel, T. A., Shah, B. R., Lau, E., Ma, R. C., So, W.-Y., Kong, A. P., Chow, E., Chan, J. C. N., & Luk, A.
- ORCID
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-09-18
- Volume
- 17
- Issue
- 9
- Pages
- e1003316
- ISSN
- 1549-1676
- Cited by
- 57
- References
- 16
- Language
- en
- Funders
- Canadian Institutes of Health Research
- Clinician Investigator Program, University of Toronto
- Canadian Society of Endocrinology and Metabolism
- Royal College of Physicians and Surgeons of Canada
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study. https://app.cochat.ai/papers/10.1371/journal.pmed.1003316
- The paper
- Ke, C., Stukel, T. A., Shah, B. R., Lau, E., Ma, R. C., So, W.-Y., Kong, A. P., Chow, E., Chan, J. C. N., & Luk, A. (2020). Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1003316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.